2 results
Approved WMOWill not start
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
Approved WMORecruiting
The goal of this study is to evaluate the effect of Gladskin on usage of topical corticosteroids in patients with atopic dermatitis. Secondary goals are to retrieve information about the effect of Gladskin on clinical symptoms, quality of life,…